MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Sustained release triple drug loaded Microbaloons for management of Parkinson’s Disease

S. Bhargava (Prayagraj, India)

Meeting: 2019 International Congress

Abstract Number: 1168

Keywords: Dopamine, Entacapone, Levodopa(L-dopa)

Session Information

Date: Tuesday, September 24, 2019

Session Title: Classification of Movement Disorders

Session Time: 1:45pm-3:15pm

Location: Les Muses Terrace, Level 3

Objective: It is hypothesized that a drug delivery system that provides controlled and sustained release of PD drugs would afford better management of PD. Hollow Microbaloons composed of PMMA(polymethyl methacrylate) and poly (caprolactone) (PCL) are prepared through a modified double-emulsion technique. They are loaded with three PD drugs, i.e., levodopa (LD), carbidopa (CD), and entacapone (ENT), at a ratio of 4:1:8.

Background: Parkinson’s disease (PD) is well-known as a progressive and degenerative disease of the nervous system. The degeneration of dopaminergic neurons in the substantia nigra, and a reduction in the amount of the neurotransmitter dopamine available in the striatum relate symptoms of this disease.

Method: Microbaloons were prepared through a double emulsion (W1/O/W2) solvent evaporation method with modifications to produce hollow Microbaloons. Microbaloons were then spray coated along with ENT. The Microbaloons were analyzed for size distribution and zeta potential using Zetasizer. Shape and surface morphology were studied using SEM. Transmission electron microscope (TEM) was used as a visualizing aid for particle morpholgy. The average particle size and polydispersity index were determined by optical microscopy using a calibrated occulometer, drug entrapment, CLSM, Buoyancy tests and in-vitro drug release was studied.

Results: LD and CD are localized in both the hollow cavity and PMMA/PCL shell, while ENT is localized in the PMMA/PCL shell. Release kinetics of hydrophobic ENT is observed to be relatively slow as compared to the other hydrophilic drugs. It is further hypothesized that encapsulating ENT into PCL as a surface coating onto these Microbaloons can aid in accelerating its release. Now, these spray-coated hollow Microbaloons exhibit similar release kinetics, according to Higuchi’s rate, for all three drugs.

Conclusion: The results suggest that multiple drug encapsulation of LD, CD, and ENT in gastric floating Microbaloons could be further developed for in-vivo evaluation for the management of PD.

To cite this abstract in AMA style:

S. Bhargava. Sustained release triple drug loaded Microbaloons for management of Parkinson’s Disease [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/sustained-release-triple-drug-loaded-microbaloons-for-management-of-parkinsons-disease/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/sustained-release-triple-drug-loaded-microbaloons-for-management-of-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley